Lite Strategy (LITS) Total Non-Current Liabilities (2011 - 2026)
Lite Strategy (LITS) posted Total Non-Current Liabilities of -$1.0 million for Q1 2026, down 14.79% on a QoQ basis from -$913000.0 in Q4 2025, and up 71.38% year-over-year from -$611500.3 in Q1 2025.
Analysis
Lite Strategy (LITS) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Lite Strategy has reported Total Non-Current Liabilities for 10 years, with the latest figure at -$1.0 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 71.38% year-over-year to -$1.0 million in Q1 2026; TTM through Mar 2026 was -$1.0 million, a 71.38% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, down 83.79% from the prior year.
- Total Non-Current Liabilities was -$1.0 million for Q1 2026 at Lite Strategy, down from -$913000.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $125.8 million in Q3 2022, with the low at -$3.7 million in Q1 2025.
- Average Total Non-Current Liabilities over 5 years is $41.9 million, with a median of $14.2 million recorded in 2023.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities tumbled 123.89% in 2025, then soared 71.38% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $99.2 million in 2022, then plunged by 85.74% to $14.2 million in 2023, then plunged by 118.47% to -$2.6 million in 2024, then soared by 65.06% to -$913000.0 in 2025, then retreated by 14.79% to -$1.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at -$1.0 million (Q1 2026), -$913000.0 (Q4 2025), and -$932000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | -1.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1.05 Mn |
| Dec 31, 2025 | -913,000.00 |
| Sep 30, 2025 | -932,000.00 |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | -3.66 Mn |
| Dec 31, 2024 | -2.61 Mn |
| Sep 30, 2024 | -2.03 Mn |
| Jun 30, 2024 | 8.36 Mn |
| Mar 31, 2024 | 15.33 Mn |
| Dec 31, 2023 | 14.15 Mn |
| Sep 30, 2023 | 14.99 Mn |
| Jun 30, 2023 | 96.19 Mn |
| Mar 31, 2023 | 99.83 Mn |
| Dec 31, 2022 | 99.23 Mn |
| Sep 30, 2022 | 125.78 Mn |
| Jun 30, 2022 | 123.82 Mn |
| Mar 31, 2022 | 125.09 Mn |
| Dec 31, 2021 | 121.82 Mn |
| Sep 30, 2021 | 122.25 Mn |
| Jun 30, 2021 | 102.23 Mn |